GT BIOPHARMA INC (GTBP) Earnings History & Surprises

NASDAQ:GTBPUS36254L3087

Current stock price

0.427 USD
+0 (+0.49%)
Last:

GTBP Earnings overview

Past quarterly earnings results for GT BIOPHARMA INC (GTBP), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).

Earnings Snapshot

Next Earnings Date

Upcoming
Release Date
May 13, 2026
Period
Q1 / 2026
EPS Estimate
-$0.08
Revenue Estimate

Last Reported

Most Recent
Release Date
Mar 2, 2026
Period
Q4 / 2025
EPS Reported
-$0.02
EPS Surprise
91.09%
Revenue Surprise
%

Beat Rate

Last 8 Quarters
0%
EPS and Revenue beats vs estimates

Quarterly Earnings Historical Results

EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.

QuarterEPSEPS EstEPS SurpriseEPS Q2QRevenueRevenue EstRevenue SurpriseRevenue Q2Q
Q4 2025 -0.02 -0.22 91.09% 98.80% - -
Q3 2025 -0.79 -0.39 -103.82% 71.31% - -
Q2 2025 -0.52 -0.69 25.03% 81.12% - -
Q1 2025 -0.33 -0.65 49.45% 79.88% - -
Q4 2024 -1.66 -1.58 -5.00% 24.20% - -
Q3 2024 -2.75 - -53.00% - -
Q2 2024 -2.75 - -83.60% - -
Q1 2024 -1.64 -2.75 40.45% -446.67% - -
Q4 2023 -2.19 -2.75 20.48% 59.44% - -
Q3 2023 -1.80 -3.06 41.18% 72.73% - -
Q2 2023 -1.50 -3.06 50.98% 50.00% - -
Q1 2023 -0.30 -4.44 93.24% 94.12% - -
Q4 2022 -5.40 -5.36 -0.84% 65.38% - -
Q3 2022 -6.60 -3.37 -96.08% -15.79% - -
Q2 2022 -3.00 -5.36 43.98% 23.08% - -
Q1 2022 -5.10 -9.49 46.24% 90.71% - -
Q4 2021 -15.60 -6.32 -146.68% 84.66% - -
Q3 2021 -5.70 -6.43 11.30% - - -
Q2 2021 -3.90 -8.47 53.93% - - -
Q1 2021 -54.90 -7.50 -632.29% - - -
Q4 2020 -101.70 -1.38 -7,285.62% - - -
Q3 2020 - - - -
Q2 2020 - - - -
Q1 2020 - - - -

Notes

  • EPS and Revenue values are non-GAAP when available, otherwise GAAP.
  • Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
  • Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
  • Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.

Earnings Q2Q Performance Trends

EPS Historical Q2Q growth and Acceleration

GTBP EPS Q2Q GrowthGTBP EPS Q2Q GrowthEPS Q2Q Growth Q4/21 Q1/22 Q2/22 Q3/22 Q4/22 Q1/23 Q2/23 Q3/23 Q4/23 Q1/24 Q2/24 Q3/24 Q4/24 Q1/25 Q2/25 Q3/25 Q4/25 Q1/26 0 -100 -200 -300 -400

Revenue Historical Q2Q growth and Acceleration

Surprise distribution (Last 4 Quarters)

EPS beat statistics

EPS beat (4)
2
Average EPS beat (4)
-8.58%
Max EPS beat (4)
49.45%
Min EPS beat (4)
-103.82%

Revenue beat statistics

Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A

Analysis

In the last 4 quarters, GTBP has beaten EPS estimates in 2 out of 4 releases
In the last 4 quarters, GTBP reported -8.6% below the EPS estimates on average.

GT BIOPHARMA INC / GTBP Earnings FAQ

What is the most recent earnings date for GTBP stock?

GT BIOPHARMA INC (GTBP) last reported earnings on 3/2/2026.

Did GT BIOPHARMA INC (GTBP) beat earnings estimates last quarter?

GT BIOPHARMA INC (GTBP) beat EPS estimates and missed revenue estimates in the most recent quarter.

How often does GT BIOPHARMA INC (GTBP) beat earnings estimates?

In the last 4 quarters, GT BIOPHARMA INC (GTBP) has beaten EPS estimates in 2 out of 4 releases.